Hazlett, Burt & Watson’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$180K Buy
1,114
+7
+0.6% +$1.17K 0.05% 275
2026
Q2
$209K Buy
1,107
+28
+3% +$5.27K 0.06% 259
2026
Q1
$212K Buy
1,079
+129
+14% +$24.9K 0.07% 240
2025
Q4
$175K Hold
950
– – 0.06% 268
2025
Q3
$146K Hold
950
– – 0.05% 271
2025
Q2
$134K Sell
950
-12
-1% -$1.68K 0.05% 243
2025
Q1
$142K Hold
962
– – 0.06% 233
2024
Q4
$126K Buy
962
+48
+5% +$6.72K 0.06% 252
2024
Q3
$143K Buy
914
+58
+7% +$9.36K 0.07% 242
2024
Q2
$133K Buy
856
+232
+37% +$34.9K 0.07% 234
2024
Q1
$86K Hold
624
– – 0.05% 264
2023
Q4
$82K Sell
624
-40
-6% -$5.2K 0.06% 244
2023
Q3
$91K Buy
664
+301
+83% +$41.1K 0.07% 226
2023
Q2
$52K Buy
363
+6
+2% +$883 0.04% 292
2023
Q1
$50K Hold
357
– – 0.04% 276
2022
Q4
$48K Buy
357
+100
+39% +$12.5K 0.04% 274
2022
Q3
$28K Buy
257
+145
+129% +$18.4K 0.03% 331
2022
Q2
$15K Hold
112
– – 0.01% 408
2022
Q1
$15K Buy
+112
New +$13.4K 0.01% 421

Other funds holding AZN

Hazlett, Burt & Watson's AZN Position: Q3 2026 in Review

Hazlett, Burt & Watson increased its AstraZeneca (AZN) stake by 0.63% in Q3 2026, buying an estimated $1.17K and bringing the position to 1,114 shares worth $180K. The position accounts for 0.05% of the portfolio, ranked #275.

Hazlett, Burt & Watson first reported a position in AZN in Q1 2022 and has held it in 19 quarters since. The position peaked at $212K in Q1 2026. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Hazlett, Burt & Watson held 1,114 shares of AstraZeneca worth $180K as of Q3 2026.
  • Hazlett, Burt & Watson bought 7 AstraZeneca shares in Q3 2026, an estimated $1.17K.
  • AstraZeneca made up 0.05% of Hazlett, Burt & Watson's portfolio in Q3 2026, its #275 holding.
  • Hazlett, Burt & Watson first reported a position in AstraZeneca in Q1 2022 and has held it in 19 quarters since.
  • Hazlett, Burt & Watson's AstraZeneca position peaked at $212K in Q1 2026.
  • 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q3 2026, filed 4 Nov 2026.